Literature DB >> 33028674

More expansive horizons: a review of endovascular therapy for patients with low NIHSS scores.

David J McCarthy1, Daniel A Tonetti1, Jeremy Stone1, Robert M Starke2,3, Sandra Narayanan4, Michael J Lang1, Ashutosh P Jadhav4, Bradley A Gross5.   

Abstract

While the landmark 2015 stroke trials demonstrated that endovascular therapy (EVT) was superior to medical management for the treatment of acute ischemic stroke due to large vessel occlusion, the efficacy of EVT for patients presenting with a low NIHSS score remains undetermined. We conducted a review of the EVT low National Institutes of Health Stroke Scale (NIHSS) stroke literature, identifying 24 quantitative and six qualitative publications. Details of study designs and outcome were extracted and critically discussed.All identified qualitative studies were retrospective. There was significant study design heterogeneity, with 18 unique study designs between the 24 identified quantitative manuscripts. Study investigations included low NIHSS EVT feasibility (n=6), EVT versus best medical management (BMM; n=10), EVT versus intravenous therapy (IVT, n=3), and low NIHSS score versus high NIHSS score (n=3). From single-arm EVT feasibility studies, the reported ranges of modified Thrombolysis in Cerebral Infarction and symptomatic intracranial hemorrhage were 78-97% and 0-10%, respectively. The EVT versus BMM literature had heterogeneous results with 40% reporting benefit with EVT and 60% reporting neutral findings. None of the studies comparing EVT with IVT reported a difference between the two revascularization therapies. The four identified meta-analyses had incongruent inclusion criteria and conflicting results. Two randomized trials are currently investigating EVT in patients with a low NIHSS score. Selected meta-analyses do suggest a potential benefit of EVT over BMM; however, current and future randomized clinical trials will better elucidate the efficacy of EVT in this patient population. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  stroke; thrombectomy; thrombolysis

Mesh:

Year:  2020        PMID: 33028674     DOI: 10.1136/neurintsurg-2020-016583

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Characterizing reasons for stroke thrombectomy ineligibility among potential candidates transferred in a hub-and-spoke network.

Authors:  Robert W Regenhardt; Amine Awad; Andrew W Kraft; Joseph A Rosenthal; Adam A Dmytriw; Justin E Vranic; Anna K Bonkhoff; Martin Bretzner; Mark R Etherton; Joshua A Hirsch; James D Rabinov; Aneesh B Singhal; Natalia S Rost; Christopher J Stapleton; Thabele M Leslie-Mazwi; Aman B Patel
Journal:  Stroke Vasc Interv Neurol       Date:  2022-05-20

2.  National implementation of reperfusion for acute ischaemic stroke in England: How should services be configured? A modelling study.

Authors:  Michael Allen; Kerry Pearn; Gary A Ford; Phil White; Anthony G Rudd; Peter McMeekin; Ken Stein; Martin James
Journal:  Eur Stroke J       Date:  2021-12-23

3.  Effectiveness and safety of EVT in patients with acute LVO and low NIHSS.

Authors:  Beom Joon Kim; Bijoy K Menon; Joonsang Yoo; Jung Hoon Han; Bum Joon Kim; Chi Kyung Kim; Jae Guk Kim; Joon-Tae Kim; Hyungjong Park; Sung Hyun Baik; Moon-Ku Han; Jihoon Kang; Jun Yup Kim; Keon-Joo Lee; Jong-Moo Park; Kyusik Kang; Soo Joo Lee; Jae-Kwan Cha; Dae-Hyun Kim; Jin-Heon Jeong; Tai Hwan Park; Sang-Soon Park; Kyung Bok Lee; Jun Lee; Keun-Sik Hong; Yong-Jin Cho; Hong-Kyun Park; Byung-Chul Lee; Kyung-Ho Yu; Mi-Sun Oh; Dong-Eog Kim; Wi-Sun Ryu; Kang-Ho Choi; Jay Chol Choi; Joong-Goo Kim; Jee-Hyun Kwon; Wook-Joo Kim; Dong-Ick Shin; Kyu Sun Yum; Sung-Il Sohn; Jeong-Ho Hong; Chulho Kim; Sang-Hwa Lee; Juneyoung Lee; Mohammed A Almekhlafi; Andrew Demchuk; Hee-Joon Bae
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

4.  Mechanical Thrombectomy: Review.

Authors:  Chintan Prajapati; Vikram Huded; Niranjan Mahajan; Anirudh Kulkarni
Journal:  Ann Indian Acad Neurol       Date:  2022-06-09       Impact factor: 1.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.